Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems
January 09, 2023 07:00 ET
|
Renalytix AI, Inc.
LONDON and SALT LAKE CITY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the execution of a Co-operative Research and Development Agreement (CRADA) with...
Primary Care Use of KidneyIntelX in Early Stage CKD Improved Clinical Care Delivery and Outcomes
December 01, 2022 07:00 ET
|
Renalytix AI, Inc.
LONDON and SALT LAKE CITY, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced additional highlights from the publication of data from a clinical utility study...
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2023
November 30, 2022 07:00 ET
|
Renalytix AI, Inc.
LONDON and SALT LAKE CITY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical...
Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease
November 29, 2022 07:00 ET
|
Renalytix AI, Inc.
Risk scoring by KidneyIntelX resulted in a 4.5-fold increase in new drug prescriptions (for SGLT2 inhibitors) for high risk compared to low risk patients, an observed reduction of HbA1c levels in the...
Renalytix to Report Financial Results for First Quarter Fiscal Year 2023 on November 30
November 22, 2022 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2023 financial results on Wednesday,...
Renalytix to Present at Stifel Healthcare Conference
November 03, 2022 07:00 ET
|
Renalytix plc
NEW YORK and SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will participate in the Stifel Healthcare Conference to be held...
Renalytix Reports Full Year Fiscal 2022 Results
October 31, 2022 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical...
Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31
October 24, 2022 07:00 ET
|
Renalytix plc
NEW YORK and SALT LAKE CITY, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its fourth quarter and full year fiscal 2022 financial...
KidneyIntelX Clinical Utility and Health Economics Validated in Multiple Data Releases at American Society of Nephrology
October 17, 2022 07:00 ET
|
Renalytix plc
NEW YORK and SALT LAKE CITY, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that four scientific presentations have been accepted at the upcoming American...
Renalytix Announces Change to Board of Directors
September 20, 2022 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that Ann Berman, non-executive director and chair of the audit and nomination...